Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...
—Metabolic dysfunction-associated steatohepatitis (MASH) isn’t just limited to older adults. According to a new study, MASH incidence is rising in younger people, making it critical to create ...
Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...
News Medical on MSN3d
Vitamin E significantly improves liver health in MASH patients, new study findsA 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...
Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...
A phase 3 trial of lanifibranor, a pan-PPAR agonist, in patients with MASH and liver fibrosis is ongoing. But with the 96.6 ...
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...
Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback